Parkinson’s Disease Market Snapshot: A Wave Of Drugs For Symptoms
Several drugs that address symptoms of the neurodegenerative disease are moving closer to market, presenting interesting commercial opportunities despite the fact that a disease-modifying breakthrough remains elusive.
You may also be interested in...
NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval
NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.
Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.
Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.